Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
SOUTH SAN FRANCISCO, Calif., May 01, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it will report its first quarter 2017 financial results on Monday, May 8, 2017 after the close of the U.S. financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
LIVE access on Monday, May 8, 2017
- 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
- Telephone 877.719.9786 (domestic) or 719.325.4773 (international); conference ID 3868586
- Webcast available at http://public.viavid.com/index.php?id=124076
REPLAY access
- Telephone replay will be available for 30 days beginning at approximately 7:30 p.m. Eastern Time on Monday, May 8, 2017 by calling 844.512.2921 (domestic) or 412.317.6671 (international); conference ID 3868586
- Webcast replay will be available on the Achaogen website at www.achaogen.com in the Investors section and will be archived for 30 days following the presentation
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Source: Achaogen, Inc. (AKAO)
Investor Contact: Hans Vitzthum 212.915.2568 [email protected] Media Contact: Denise Powell 510.703.9491 [email protected]
